Hepatitis B clinical trials

Explore recruiting hepatitis b clinical trials.

Recruiting hepatitis b studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hepatitis B trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

TherVacB – A multi-center phase 1b/2a trial to assess safety, tolerability and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine candidate

Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Effectiveness and Safety of Intra-Dermal Hepatitis B Vaccination after topical application of IMIQUIMOD, in cirrhotic patients, who did not respond to the conventional vaccine regimen: a pilot study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tide analogue (NA) therapy.

Belgium, Germany, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Participants living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment

France, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

HepBTer: From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)

Denmark, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Hepatitis B trials by city

Hepatitis B in Toronto Hepatitis B in Vancouver Hepatitis B in Montreal Hepatitis B in Calgary Hepatitis B in Edmonton Hepatitis B in Ottawa Hepatitis B in Winnipeg Hepatitis B in Quebec City Hepatitis B in Hamilton Hepatitis B in Kitchener Hepatitis B in London Hepatitis B in Halifax Hepatitis B in New York Hepatitis B in Los Angeles Hepatitis B in Chicago Hepatitis B in Houston

Other conditions

Kidney cancer Liver cancer Glioblastoma Head and neck cancer Cervical cancer Endometrial cancer Gastric cancer Age-related macular degeneration Diabetic retinopathy Glaucoma Dry eye disease HIV Hepatitis C COVID-19 Influenza RSV Sickle cell disease Anemia Hemophilia Thalassemia Chronic pain Low back pain Smoking cessation Tinnitus